Provided by Tiger Trade Technology Pte. Ltd.

Veracyte

40.87
-1.1600-2.76%
Post-market: 40.870.00000.00%19:30 EDT
Volume:1.00M
Turnover:41.20M
Market Cap:3.29B
PE:29.31
High:42.66
Open:42.61
Low:40.79
Close:42.03
52wk High:60.91
52wk Low:29.46
Shares:80.39M
Float Shares:78.97M
Volume Ratio:1.02
T/O Rate:1.27%
Dividend:- -
Dividend Rate:- -
EPS(TTM):1.39
EPS(LYR):0.8200
ROE:8.77%
ROA:4.09%
PB:2.37
PE(LYR):49.84

Loading ...

UBS Adjusts Price Target on Veracyte to $65 From $52, Keeps Buy Rating

MT Newswires Live
·
Sep 09

Veracyte Director Muna Bhanji Disposes of 1,864 Common Shares Worth $80,086.08

Reuters
·
Sep 04

Veracyte to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

GlobeNewswire
·
Sep 02

Veracyte (VCYT) Receives a Buy from Piper Sandler

TIPRANKS
·
Aug 24

Veracyte (VCYT) Dropped, So What Is Behind The Latest Attention?

Simply Wall St.
·
Aug 11

Veracyte price target lowered to $54 from $66 at Piper Sandler

TIPRANKS
·
Aug 04

Veracyte (VCYT) Is Down 18.2% After Raising 2026 Revenue Guidance on New Cancer Tests

Simply Wall St.
·
Aug 04

Veracyte is Maintained at Hold by Canaccord Genuity

Dow Jones
·
Aug 04

Guggenheim Reaffirms Their Buy Rating on Veracyte (VCYT)

TIPRANKS
·
Aug 03

Veracyte falls -24.0%

TIPRANKS
·
Jul 31

Needham Raises Price Target on Veracyte to $69 From $57, Keeps Buy Rating

MT Newswires Live
·
Jul 31

Veracyte: Strong Earnings Beat, Raised Guidance and Emerging Diagnostics Portfolio Support Durable Upside, Justifying Buy Rating

TIPRANKS
·
Jul 31

Veracyte Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Jul 31

Veracyte Q2 Non-GAAP Earnings, Revenue Rise; 2026 Revenue Guidance Raised

MT Newswires Live
·
Jul 31

GUIDANCE: (VCYT) Veracyte Now Expects Full Year 2026 Revenue Range $590 Million - $596 Million, vs. FactSet Est of $586.4 Million

MT Newswires Live
·
Jul 31

Veracyte raises FY26 revenue view to $590M-$596M from $582M-$592M

TIPRANKS
·
Jul 31

Veracyte Q2 FY26 Swings to GAAP Net Income of $25.5 Million; Revenue Rises 15% to $150.3 Million

Reuters
·
Jul 31

Veracyte Q2 Revenue Rises on Decipher and Afirma Test Sales

Reuters
·
Jul 31

Veracyte Q2 Revenue USD 150.3 Million Vs. IBES Estimate USD 144.6 Million

Reuters
·
Jul 31

Veracyte Q2 Adj. EPS $0.54 Beats $0.24 Estimate, Sales $150.321M Beat $144.554M Estimate

Benzinga Earnings
·
Jul 31